Apogee Q2 2024 Earnings Report

Apogee Therapeutics reported pipeline progress and second quarter 2024 financial results.

Key Takeaways

Apogee Therapeutics reported pipeline highlights and second quarter financial results, with a focus on advancing its pipeline, including APG777, APG808, and APG990, and adding APG333 to its portfolio. The company plans combination studies and has a cash runway into 2028.

Continued advancement of pipeline and execution towards expected milestones.

APG333, a novel subcutaneous half-life extended anti-TSLP antibody, was added to portfolio.

Apogee plans combination studies of 777 + 990 (IL-13 and OX40L) and 777 + 333 (IL-13 and TSLP).

$790 million cash, cash equivalents and marketable securities with runway into 2028.

Previous year: -$3.78

-84.1%

R&D expenses (Q2)

$33.2M